Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 2, 2019International Journal of Neonatal ScreeningOpen Access

Development of a Multiplex Real-Time PCR Assay for the Newborn Screening of SCID, SMA, and XLA

View Full Paper
Ask AI
Bookmark
Share

Key result

A novel four-plex real-time PCR assay demonstrated reliability and analytical accuracy in screening for SCID, XLA, and SMA using over 3,000 newborn dried blood spot samples.

Why the study?

Universal newborn screening provides clear benefits for primary immunodeficiencies and spinal muscular atrophy, motivating the development of a multiplex assay to screen for these conditions simultaneously.

Population

Over 3000 DNA samples from putative normal newborn dried blood spots, controls, and confirmed positive samples

Comparison

Four-plex real-time PCR assay for SCID, XLA, and SMA screening

Design

Assay development and analytical validation study

Authors

CGCristina Gutiérrez-MateoATAnne TimonenKVKatja Vaahtera

Discussion

Loading...

Member takes

Overview

Four-plex DBS PCR assay enables combined SCID/XLA/SMA screening; leaves open prospective validation before clinical adoption.

Structured PICO

P
Population
Over 3,000 DNA samples from putative normal newborn dried blood spots, along with controls and confirmed positive samples, were used to evaluate a multiplex real-time PCR assay.
I
Intervention
Four-plex real-time PCR assay to screen for Severe Combined Immune Deficiencies (SCID), X-linked agammaglobulinemia (XLA), and Spinal Muscular Atrophy (SMA) from a single 3.2 mm DBS punch.
O
Outcome
Assay performance, reliability, and analytical accuracy.

A newly developed four-plex real-time PCR assay enables efficient, high-throughput simultaneous newborn screening for SCID, SMA, and XLA from a single dried blood spot.

Cite This Study

Gutiérrez-Mateo et al. (2019) studied Severe Combined Immune Deficiencies (SCID), X-linked agammaglobulinemia (XLA), and Spinal Muscular Atrophy (SMA) (n=3,000). Multiplex real-time PCR assay was evaluated on Assay performance, reliability, and analytical accuracy. A novel four-plex real-time PCR assay demonstrated reliability and analytical accuracy in screening for SCID, XLA, and SMA using over 3,000 newborn dried blood spot samples.

synapsesocial.com/papers/6a5e3e34a5f26c43a2d8a67chttps://doi.org/10.3390/ijns5040039
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Quality considerations and major pitfalls for high throughput DNA-based newborn screening for severe combined immunodeficiency and spinal muscular atrophy2024 · 2 citations
  2. 2Newborn Blood Spot Screening Test Using Multiplexed Real-Time PCR to Simultaneously Screen for Spinal Muscular Atrophy and Severe Combined Immunodeficiency2014 · 87 citations
  3. 3Validation on the First-Tier Fully Automated High-Throughput SMN1, SMN2, TREC, and RPP30 Quantification by Quadruplex Droplet Digital PCR for Newborn Screening for Spinal Muscular Atrophy and Severe Combined Immunodeficiency2025
  4. 4Multiplex Real-Time PCR-Based Newborn Screening for Severe Primary Immunodeficiency and Spinal Muscular Atrophy in Osaka, Japan: Our Results after 3 Years2024 · 10 citations
  5. 5A new line method; A direct test in spinal muscular atrophy screening for DBS2023 · 2 citations